We have investigated the eect of inducing apoptosis in BJAB and Jurkat cells on the cellular content of several polypeptide chain initiation factors. Serum deprivation results in inhibition of protein synthesis and induction of apoptosis in BJAB cells; at early times, there is selective degradation of polypeptide initiation factor eIF4G but no major losses of other key initiation factors. The disappearance of full length eIF4G is accompanied by the appearance of smaller forms of the protein, including a major product of approximately 76 kDa. Apoptosis induced by cycloheximide results in similar eects. Both total cytoplasmic eIF4G and eIF4G associated with eIF4E are degraded with a half-life of 2 ± 4 h under these conditions. Treatment of serum-starved or cycloheximide-treated cells with Z-VAD.FMK or Z-DEVD.FMK, which inhibit caspases required for apoptosis, protects eIF4G from degradation and blocks the appearance of the ca. 76 kDa product. Exposure of BJAB cells to rapamycin rapidly inhibits protein synthesis but does not lead to acute degradation of eIF4G. In both BJAB and Jurkat cells induction of apoptosis with anti-Fas antibody or etoposide also results in the selective loss of eIF4G, which is inhibitable by Z-VAD.FMK. These data suggest that eIF4G is selectively targeted for cleavage as cells undergo apoptosis and is a substrate for proteases activated during this process.
Introduction
The initiation of protein synthesis is regulated by complex interactions between a large number of protein initiation factors and RNA molecules (Pain, 1996; Merrick and Hershey, 1996) . Disruption of this process can lead to transformation of cells to an oncogenic phenotype, probably as a result of aberrant expression of proteins involved in the control of cell growth or cell death . Many of the steps in the initiation pathway require speci®c protein ± protein interactions between individual initiation factors as well as between these factors and the ribosome. It is now established that the large polypeptide chain initiation factor eIF4G plays a crucial role in these interactions by acting as a bridge between other components such as the mRNA capbinding protein eIF4E and the multi-subunit eIF3 complex, which allows the mRNA molecule to associate with the 40S ribosomal subunit (reviewed in Merrick and Hershey, 1996; Morley et al., 1997) . In mammalian cells initiation factor eIF4G is a single polypeptide chain of 154 kDa (Yan et al., 1992) which exists in vivo at least partly in the form of a trimeric complex with eIF4E and the ATP-dependent RNA helicase eIF4A, constituting the large initiation factor eIF4F (Merrick, 1994) . Recently a second form of human eIF4G has also been described (Gradi et al., 1998) . eIF4G possesses domains for the binding of eIF4E and eIF3 in the N-terminal and central parts of its sequence respectively, and it also has binding sites for eIF4A (Lamphear et al., 1995; and, at least in yeast, for the poly(A) binding protein (PABP) (Tarun and Sachs, 1996; Le et al., 1997; Tarun et al., 1997) . Interaction of PABP with eIF4G or with the recently discovered eIF4G homologue PAIP (Craig et al., 1998) may allow functional association of the 3' end of an mRNA with the 5' end, thus eectively causing`circularization' of the mRNA during protein synthesis (Tarun et al., 1997) .
The association of eIF4G with eIF4E strongly enhances the binding of the latter to 5' mRNA cap structures (Haghighat and Sonenberg, 1997) . However this interaction is inhibited by a small family of 4E binding proteins (4E-BPs) which can compete with eIF4G for binding to eIF4E Haghighat et al., 1995; Altmann et al., 1997; Matsuo et al., 1997) . The extent of complex formation between the best studied of these proteins, 4E-BP1 (also known as PHAS-I) (Lawrence and , and eIF4E is regulated by the phosphorylation of 4E-BP1 (Graves et al., 1995; Von Manteuel et al., 1996; Brunn et al., 1997) . This phosphorylation is activated by a pathway which can be inhibited by the macrolide immunosuppressant, rapamycin Von Manteuel et al., 1996; Beretta et al., 1996a; Fadden et al., 1997; Brunn et al., 1997) . As a result rapamycin inhibits cap-dependent initiation (Beretta et al., 1996a,b) , as well as antagonizing increases in protein synthesis brought about by mitogenic stimuli . In some eukaryotic systems, notably the yeast Saccharomyces cerevisiae, rapamycin also inhibits the basal rate of protein synthesis (Barbet et al., 1996) , although it is not yet clear whether the same mechanisms are responsible for the eects of rapamycin in yeast and mammalian cells (Altmann et al., 1997; Thomas and Hall, 1997) . Enhancement of protein synthesis at the translational level by mitogens is also associated with the increased phosphorylation of eIF4E at position Ser 209 (Joshi et al., 1995; Flynn and Proud, 1995) , as well as the phosphorylation of eIF4G itself (Morley and Pain, 1995a,b) .
In addition to regulation by alterations in the activity of eIF4E and eIF4G via protein phosphorylation, protein synthesis can be modulated by changes in the levels of these factors in the cell. Over-expression of eIF4E or eIF4G in NIH-3T3 cells can result in the transformation of these cells into a malignant phenotype (Lazaris-Karatzas et al., 1990; FukuchiShimogori et al., 1997) and it has been proposed that this is due to the enhanced translation of normally inecient mRNAs with complex secondary structures in their 5' untranslated regions (Koromilas et al., 1992) . Conversely, down-regulation of eIF4E expression causes a strong inhibition of protein synthesis, decreases cell growth rates and impairs malignancy (De Benedetti et al., 1991; Gra et al., 1995) . (Note, however, that the level of eIF4G also falls dramatically when eIF4E is depleted (De Benedetti et al., 1991) so it is not possible to say which factor is the more important in bringing about these phenotypic consequences). High levels of expression of eIF4E and, in some cases, of eIF4G have been found in a variety of malignant human tumours (Miyagi et al., 1995; Li et al., 1997; Nathan et al., 1997a,b; Brass et al., 1997) , but it is not known whether this is due to enhanced synthesis or a slower rate of degradation of these initiation factors. Elevated levels of mRNA for eIF4E are seen in cells transformed with the oncogene c-myc (Rosenwald et al., 1993) , as well as in normal T lymphocytes after activation by mitogens (Mao et al., 1992) . Dramatic changes occur in the level and integrity of eIF4G in mammalian cells after infection with certain picornaviruses such as polio or foot-and-mouth-disease viruses. Within a few hours of infection eIF4G is cleaved at speci®c internal sites by virally-encoded proteases to yield de®ned N-terminal and C-terminal fragments (reviewed in Morley et al., 1997) . Since the cleavages occur in a region between the eIF4E and eIF3 binding sites (Lamphear et al., 1993) they destroy the bridging function of eIF4G in protein synthesis and thus lead to the inhibition of cap-dependent initiation. However the remaining C-terminal fragment of eIF4G can still support the initiation of protein synthesis that involves ribosome binding to internal sites on mRNAs (and is therefore cap-independent; Pestova et al., 1996) . As a result picornavirus RNA-directed protein synthesis, which occurs by internal initiation, is favoured in cells in which eIF4G has been cleaved. It is not yet clear whether a similar mechanism is used to inhibit cap-dependent protein synthesis in uninfected cells (in which a small number of cellular mRNAs may also be translated by an internal initiation mechanism), although there are a few reports of the cleavage of eIF4G under situations where protein synthesis is down-regulated by physiological stimuli such as brain ischaemia and reperfusion (DeGracia et al., 1996) and induced dierentiation of erythroleukaemia cells (Benton et al., 1996) . The presence of several PEST sequences in eIF4G suggests that this factor might be subject to rapid degradation under some circumstances .
Because potential increases in eIF4G activity (as a result of enhanced expression or increased binding to eIF4E) are associated with the responses of cells to mitogenic stimuli, and because eIF4G itself is apparently able to induce cell growth when overexpressed (Fukuchi-Shimogori et al., 1997), we have investigated whether down-regulation of the factor may also be seen under conditions where cells are subjected to growth inhibitory and death-inducing stimuli. To study this we have chosen to use human B and T lymphocyte-derived tumour cell lines, viz. BJAB and Jurkat cells respectively, since such cell types are sensitive to a wide range of physiological signals that can inhibit proliferation and induce apoptosis (programmed cell death). Examples of such conditions include deprivation of serum growth factors (Kawanishi, 1997), inhibition of protein synthesis with cycloheximide (Ishii et al., 1995 , treatment with antibodies to the CD95 Fas antigen (Oehm et al., 1992; Juo et al., 1997) , or exposure to etoposide, an inhibitor of DNA topoisomerase II (Sinha, 1995) . Apoptosis is characterized by a series of cellular changes that lead ultimately to cell death (Hale et al., 1996; Rowan and Fisher, 1997; Nagata, 1997; Salvesen and Dixit, 1997 ). An essential aspect of these events is the sequential activation of a number of proteases with limited substrate speci®cities, the caspases (Fearnhead et al., 1995; Tewari et al., 1995; Enari et al., 1996; Salvesen and Dixit, 1997; Cohen, 1997; Longthorne and Williams, 1997; Ohta et al., 1997) . Intensive research in recent years has investigated the properties of these enzymes, the nature of some of their substrates, and their relative relationships in the protease cascades required for execution of the apoptotic programme.
We report here that eIF4G is degraded as part of the apoptotic response in BJAB cells and Jurkat cells. Cleavage of eIF4G to give smaller discrete products occurs contemporaneously with other events associated with apoptosis and is blocked by caspase inhibitors, suggesting that the initiation factor may be a substrate for apoptotic proteases in vivo. The signi®cance of the loss of intact eIF4G for changes in protein synthesis during programmed cell death is discussed.
Results

Eects of serum deprivation on protein synthesis, levels of initiation factors and induction of apoptosis in BJAB cells
Protein synthesis in BJAB cells is very sensitive to serum deprivation. As shown in Figure 1 , the incorporation of [ 35 S]methionine into acid-insoluble material declines by more than 60% within 24 h of placing the cells in 0.1% foetal calf serum. After 2 days of this treatment incorporation is reduced to 11% of the control value. We have investigated the extent to which this decrease in translational activity is associated with the loss of key factors required for polypeptide chain initiation. As shown in Figure 2a (and quanti®ed in panel B), after 24 h of serum deprivation there is a marked disappearance of initiation factor eIF4G to about 25 ± 30% of control levels, with lesser changes in the levels of eIF4E, eIF4A and 4E-BP-1. The level of eIF2a was also seen to decrease over this time, albeit at a reproducibly slower rate.
In addition to inhibition of protein synthesis and cell growth, BJAB cells undergo apoptosis when placed in low serum. This is indicated by the appearance of a speci®c 89 kDa cleavage product of the 112 kDa protein poly(ADP-ribose) polymerase (PARP) (Kaufmann et al., 1993; Duriez and Shah, 1997) , beginning within 1 h after initiation of serum deprivation ( Figure  2c ). We have observed that the loss of eIF4G under these circumstances is also accompanied by the appearance of a number of discrete fragments, the most prominent of which has an apparent size of about 76 kDa (Figure 2c ). These fragments are recognized by an anti-eIF4G serum directed against a C-terminal region of the protein (amino acids 920 ± 1396) and must therefore contain at least part of this sequence. The cleavages of eIF4G and PARP occur with essentially identical time-courses. Because of these interesting changes in the integrity of eIF4G our further studies have focused largely on this factor.
To determine whether the disappearance of eIF4G is a consequence of the induction of apoptosis or whether it is a separate response to serum deprivation, we have investigated the eects of inhibition of caspase activity in intact cells on the integrity of eIF4G. BJAB cells were deprived of serum for 1 or 2 days, in the presence or absence of the broad speci®city caspase inhibitor Z-VAD.FMK. The inhibitor was able largely to prevent eIF4G degradation over this time period (Figure 3 ). The appearance of the ca. 76 kDa product which occurred when BJAB cells were incubated in 0.1% serum was also blocked by Z-VAD.FMK (Figure 3) , as was the cleavage of PARP (data not shown). In contrast, the levels of other minor cross-reacting bands which were present both before and after serum deprivation were not aected by Z-VAD.FMK.
Cycloheximide treatment induces apoptosis and cleavage of eIF4G in BJAB cells
Incubation of BJAB cells with cycloheximide has previously been shown to inhibit protein synthesis and induce rapid apoptosis (Ishii et al., 1995 . The eects of this apoptotic agent on the levels of several initiation factors are shown in Figure 4a . It can be seen that eIF4G disappears with rapid kinetics after treatment of cells with cycloheximide. Densitometry of the immunoblots (Figure 4b) indicates that, after an initial lag, the level of the factor declines to about half its original value within 2 ± 4 h and eIF4G becomes virtually undetectable by 6 h. In contrast, eIF4E (quanti®ed in Figure 4b ), eIF2a, 4E-BP1 and eIF4A ( Figure 4a ) are quite stable after cycloheximide treatment, except at long times of exposure to the drug. Similar eects of cycloheximide were obtained with cells that had been cultured in the presence of 0.1% serum, although in this case the initial level of eIF4G was already lower (data not shown).
We have also investigated whether eIF4G that is associated with eIF4E in the eIF4F initiation factor complex is degraded in the presence of cycloheximide. eIF4E and eIF4F were isolated by anity chromatography on m 7 GTP-Sepharose and the levels of eIF4G present in eIF4F were determined by immunoblotting. As Figure 5 illustrates, eIF4G isolated by this procedure was also lost rapidly after cycloheximide treatment, with similar kinetics to the loss of total eIF4G (Figure 4) . Quanti®cation of these data indicate that cleavage of eIF4G results in a decline in eIF4F levels, as shown by the marked decline in the ratio of eIF4G to eIF4E in the m 7 GTP-Sepharose-puri®ed material ( Figure 5) .
As in the case of serum deprivation, the cycloheximide-induced disappearance of full-length eIF4G within 2 ± 4 h was accompanied by the appearance of a ca. 76 kDa fragment (Figure 6a , upper panel). The time-course of these changes exactly coincided with that of the cleavage of PARP, which yielded characteristic 89 kDa and 24 kDa cleavage products (lower panel). Preincubation of BJAB cells with the caspase inhibitors Z-VAD.FMK or Z-DEVD.FMK protected eIF4G from cycloheximide-induced degradation and blocked the appearance of the ca. 76 kDa cleavage product (Figure 6b ). However exposure of the cells to a reported inhibitor of caspase-3, ZnCl 2 (Perry et al., 1997) , was without eect in these cells. The cleavage of PARP in the cycloheximide-treated cells was also inhibited by Z-VAD.FMK and Z-DEVD.FMK but not by ZnCl 2 (data not shown).
Is inhibition of protein synthesis sucient to destabilize eIF4G?
The association of eIF4G with eIF4E in the eIF4F complex is inhibited by the eIF4E binding proteins, 4E-BP1 and 4E-BP2, which compete with eIF4G for the cap-binding factor. The 4E-binding proteins are reversibly phosphorylated in response to conditions which stimulate translation (Lin et al., 1994 Lin and Lawrence, 1996; Fadden et al., 1997; Lawrence and Abraham, 1997) and this process favours Figure 4 Changes in levels of initiation factors in cycloheximide-treated BJAB cells. Exponentially growing cells were treated with cycloheximide (100 mg/ml) for the times indicated and cytoplasmic extracts prepared as described in Materials and methods. (a) Equal quantities of protein from each extract were subjected to SDS gel electrophoresis, followed by immunoblotting for eIF4G, eIF4A, eIF4E, eIF2a and 4E-BP1. (b) Kinetics of loss of eIF4G and eIF4E following treatment with cycloheximide, analysed by scanning densitometry and expressed as the level of protein remaining relative to the untreated cells. The experiment was carried out three times and the error bars represent standard errors of the mean dissociation of their complexes with eIF4E (Sonenberg, 1996; Lawrence and . The pathway leading to these events is inhibited by rapamycin, due to impairment of the phosphorylation of the 4E-BPs Beretta et al., 1996a) . In BJAB cells overall protein synthesis is particularly sensitive to rapamycin (Kay et al., 1996) , suggesting that the eects of the drug are not limited to the translation of mRNAs with 5' terminal oligopyrimidine tracts (Jeeries et al., 1994; in this system. Thus it was of interest to determine whether inhibition of protein synthesis by this agent would also lead to increased degradation of eIF4G, as has recently been reported for Saccharomyces cerevisiae (Berset et al., 1998) . Figure 7a shows that in BJAB cells rapamycin inhibits protein synthesis by about 30% within 30 min, increasing to over 60% within 4 h. Consistent with the mode of action described above, rapamycin caused rapid dephosphorylation of 4E-BP1, together with increased association of 4E-BP1 and decreased association of eIF4G with eIF4E. However there was no signi®cant loss of fulllength eIF4G, or appearance of the ca. 76 kDa cleavage product, for up to 6 h after drug treatment (Figure 7b ). Rapamycin itself did not protect eIF4G from cleavage in cells simultaneously treated with cycloheximide (data not shown). These results indicate both that inhibition of protein synthesis per se is not sucient to cause the loss of eIF4G and that the dissociation of eIF4G from eIF4E under conditions where apoptosis is induced by another agent does not prevent such loss.
Induction of apoptosis by other agents correlates with eIF4G cleavage
We have used two other inducers of apoptosis in BJAB cells, viz. an agonistic antibody against the Fas antigen and the DNA topoisomerase inhibitor etoposide, to determine whether eIF4G cleavage is a more general Figure 5 Cycloheximide induces loss of eIF4G recovered in association with eIF4E. Aliquots of cell extracts prepared as in Figure 4 were subjected to anity chromatography on m 7 GTPSepharose to purify eIF4E and associated proteins. Samples derived from equal amounts of total cytoplasmic protein were resolved by SDS gel electrophoresis followed by immunoblotting for eIF4G and eIF4E. The immunoblots were analysed by scanning densitometry to determine the relative levels of the two factors and the ratio of eIF4G:eIF4E was calculated (in arbitrary units). The inset shows the blots from which these data were derived, which are representative of those obtained in three separate experiments Figure 6 Appearance of eIF4G cleavage products in cycloheximide-treated BJAB cells and inhibition by caspase inhibitors. Exponentially growing cells were treated with cycloheximide (100 mg/ml) for the times indicated and cytoplasmic extracts prepared as described in Materials and methods. (a) Equal quantities of protein from each extract were subjected to SDS gel electrophoresis followed by immunoblotting for eIF4G and PARP. (b) BJAB cells were preincubated with or without Z-VAD.FMK (10 mM), Z-DEVD.FMK (25 mM) or ZnCl 2 (100 mM) for 1 h and then incubated with or without cycloheximide (100 mg/ml) for 3 h. Extracts were prepared as described in Materials and methods and cleavage of eIF4G was monitored by immunoblotting. Molecular weight markers are indicated on the right of each panel and full-length eIF4G or PARP and their cleavage products are indicated on the left. These data are representative of those obtained in three separate experiments phenomenon associated with apoptosis. Treatment of BJAB cells with anti-Fas antiserum ( Figure 8 , upper panel; compare lanes 1 and 4), etoposide (compare lanes 2 and 5) or cycloheximide (compare lanes 3 and 6) all resulted in the cleavage of eIF4G and generation of the ca. 76 kDa cleavage product, albeit with varying eciency. In addition, the cleavage of PARP observed following these treatments (lower panel) followed a similar pattern. In each instance, incubation of cells in the presence of Z-VAD.FMK prevented the cleavage of eIF4G (upper panel, lanes 7 ± 9) and PARP (lower panel, lanes 7 ± 9).
Induction of apoptosis in Jurkat cells results in loss of eIF4G
To determine whether conditions which induce apoptosis have an eect on eIF4G levels in another cell type we have studied the response of the human T-cell leukaemia-derived Jurkat cell line to various inducers. Figure 9a (Figure 9a , lanes 4 ± 6) and the appearance of cells with less than the G1 content of DNA (Figure 9b ). However, cleavage of eIF4G in response to these stimuli was not prevented by use of the proteosome inhibitor, MG132, or the calpain inhibitor, calpeptin (data not shown). On the other hand, rapamycin treatment did not cause any detectable loss of eIF4G or cleavage of PARP under these conditions (compare lanes 1 and 7; see also Figure 9c , lanes 1 vs 4). As in the case of BJAB cells induction of apoptosis also depleted the amount of eIF4G associated with eIF4E ( Figure 9c , lanes 5 ± 8). In contrast there was no signi®cant reduction in the levels of eIF4E, eIF4A or poly(A)-binding protein (PABP; Figure 9c , lanes 1 ± 4), or of eIF4B or eIF2a (data not shown) in the same total cytoplasmic extracts. We did, however, observe a complete loss of the PABP that co-puri®ed with eIF4E after antiFas treatment (Figure 9c ; compare lanes 5 and 6). The latter result may indicate that PABP associates with eIF4G in mammalian eIF4F complexes, as is the case in yeast (Tarun and Sachs, 1996; Le et al., 1997) , or that interaction of PABP with the eIF4G homologue PAIP (Craig et al., 1998) is also altered in cells undergoing apoptosis. The eects of anti-Fas treatment on eIF4G and the co-puri®cation of PABP with eIF4E were blocked by Z-VAD.FMK (Figure 9c , lanes 2 vs 3 and lanes 6 vs 7), under conditions where this agent prevented the apoptotic response as measured by PARP cleavage (Figure 9a ) or the appearance of cells with less than the G1 content of DNA (Figure 9b) . 
Discussion
The initiation of protein synthesis is controlled by a variety of mechanisms that respond to many physiological signals. Dysregulation of this process (for example by over-expression of eIF4E or eIF4G (LazarisKaratzas et al., 1990; De Benedetti and Rhoads, 1990; Fukuchi-Shimogori et al., 1997) or by mutation of the phosphorylation site in eIF2a (DonzeÂ et al., 1995) can lead to aberrant growth and oncogenic transformation. Much eort has been devoted to understanding the means by which reversible phosphorylation of factors such as eIF2, eIF4E and the 4E-BPs controls protein synthesis (reviewed in Pain, 1996) . However, rather little attention has been paid to the role of acute changes in the levels of individual initiation factors in translational control, in spite of the fact that the signi®cance of the relative amounts of key factors has been a subject for keen debate (Hershey, 1994; Rau et al., 1996) . In this paper we have shown that exposure of human tumour cells of both B-and T-lymphoid origin to a variety of conditions that inhibit cell proliferation and induce apoptosis causes the rapid and selective disappearance of polypeptide chain initiation factor eIF4G. Under our conditions the eect appears relatively speci®c for eIF4G, with no major decreases in eIF4A or eIF4E but moderate eects on the level of eIF2a. In this study we have not investigated possible changes in the levels of the various subunits of eIF3, but results from other laboratories have shown that eIF3 can also be degraded rapidly under certain conditions (Naranda et al., 1996) . In contrast to our results, Neumar et al. (Neumar et al., 1995) have reported that eIF4E is also susceptible to rapid decay, with a half-life of 15 ± 20 min, but this was assayed under conditions of brain ischaemia.
Previous ®ndings have indicated that eIF4G is susceptible to rapid cleavage and disappearance of the full length protein, not only in picornavirusinfected cells Devaney et al., 1988; Kirchweger et al., 1994; Ziegler et al., 1995a) but also in uninfected HeLa cells following antisense RNAmediated down-regulation of eIF4E (De Benedetti et al., 1991) , in brain following ischaemia and reperfusion (DeGracia et al., 1996) , in erythroleukaemia cells induced to dierentiate with haemin (Benton et al., 1996) and in yeast subjected to nutritional deprivation (Berset et al., 1998) . Thus eIF4G seems particularly susceptible to degradation, probably by a number of dierent proteolytic pathways depending on the cell type and stimulus. The stability of eIF4G may be determined not only by the signalling pathways by which cells respond to stresses but also by the other proteins with which the factor associates. Binding sites for eIF4E, eIF4A, eIF3 and PABP have been characterized on eIF4G from various eukaryotic sources (Tarun and Sachs, 1996; Morley et al., 1997; Le et al., 1997; . The in¯uence of these proteins on eIF4G stability in vivo remains unknown. However the eIF4G/eIF4E complex is a target for direct cleavage by rhinovirus 2A protease (Haghighat et al., 1996) , and we have previously suggested that eIF4E may be required to allow the cleavage of eIF4G by the foot-and-mouth disease virus L-protease (Ohlmann et al., 1997) . In the present study we have shown that total cytoplasmic eIF4G disappears with similar kinetics to eIF4G that is associated with eIF4E. However this does not con¯ict with the previous observations using L-protease since eIF4G probably exchanges rapidly in and out of complexes with eIF4E in vivo. In addition, preliminary data suggest that the apoptosis-induced cleavage of eIF4G occurs at a site(s) distinct to that of L-protease since the ca. 76 kDa cleavage fragment still binds to eIF4E and can itself be cleaved by the viral protease (M. Bushell, unpublished data). Further characterization of the apoptosis-speci®c cleavage of eIF4G will be published elsewhere. The fact that several disparate inducers of apoptosis, which probably act by dierent mechanisms (Boix et al., 1998) , all lead to the loss of eIF4G indicates that the pathways activated by these agents converge on this target protein. Low serum conditions activate apoptosis in immortalized or transformed cell lines (Kulkarni and McCulloch, 1994; Wang and Pandey, 1995; Kawanishi, 1997) , probably by depriving the cells of growth factors necessary to promote cell cycle progression (Ohta et al., 1997) ; cycloheximide is also an ecient inducer of apoptosis in a variety of cell types, perhaps because it blocks the synthesis of one or more proteins essential for the prevention of apoptosis (Martin et al., 1990; Collins et al., 1991; Ledda-Columbano et al., 1992; Ishii et al., 1997) ; the CD95 (Fas) receptor acts by binding a number of proteins to the`death domain' located on its intracellular portion; etoposide interacts with DNA topoisomerase II and induces DNA strand breaks. The point of convergence of these pathways at the level of eIF4G is most likely the activation of one or more`executioner' caspases (Longthorne and Williams, 1997; Kamada et al., 1997; Cohen, 1997) . This is consistent with the ability of the caspase inhibitors (Z-VAD.FMK and Z-DEVD.FMK; Dolle et al., 1994; Fearnhead et al., 1995; Perry et al., 1997; Juo et al., 1997) , but not calpain or proteosome inhibitors (data not shown), to block the disappearance of eIF4G regardless of the apoptosis-inducing stimulus.
The evidence that eIF4G is degraded by a caspasemediated mechanism in response to a variety of apoptotic stimuli suggests that the initiation factor is a potential candidate to be added to the growing list of proteins that are cleaved by caspases (Martin and Green, 1995; Hale et al., 1996; Lavin et al., 1996; Chen et al., 1997; Widmann et al., 1998) . However the eects of the inhibitors Z-VAD.FMK and Z-DEVD.FMK are not sucient to indicate which caspase activity is responsible, or indeed to establish that these enzymes are the actual catalysts of eIF4G cleavage. Both Z-VAD.FMK and Z-DEVD.FMK have relatively broad speci®cities against a number of caspases (Kidd, 1998) . ZnCl 2 is an inhibitor of caspase-3 but it is not clear whether it is also active against other caspases (Perry et al., 1997) . Although it is likely that several dierent caspases become activated under the conditions of our experiments the lack of eect of ZnCl 2 on eIF4G cleavage might suggest that caspase-3 activity is not required. Studies in vitro with puri®ed or recombinant enzymes will be necessary to establish whether eIF4G is a direct substrate for caspases.
In addition to speci®c degradation it is possible that the synthesis of eIF4G may be severely impaired in apoptotic cells since conditions such as serum deprivation, cycloheximide, anti-Fas or etoposide treatment all inhibit overall translation. However, the prevention of the loss of eIF4G by the caspase inhibitors in cycloheximide-treated cells cannot be attributed to any increase in synthesis of the factor since cycloheximide completely inhibits translation when present at the concentration used here (100 mg/ ml). It is also unlikely that the decrease in the level of eIF4G under conditions where protein synthesis is inhibited is merely a re¯ection of normal rapid turnover of the protein since this would not be blocked by inhibiting caspase activities. Furthermore, studies with rapamycin (Figure 7) suggest that the inhibition of protein synthesis per se is not sucient to cause any cleavage of eIF4G in BJAB cells. This is in contrast to the situation in yeast where the factor disappears within 1 ± 2 h of rapamycin treatment (Berset et al., 1998) . Another potential mechanism by which cycloheximide might destabilize eIF4G is by promoting the phosphorylation of the 4E-BPs via activation of the mTOR/p70 S6 kinase signalling pathway (Krieg et al., 1988; Brunn et al., 1997; Fadden et al., 1997; Lawrence and Abraham, 1997) . This would have the eect of dissociating eIF4E from the 4E-BPs and favouring its association with eIF4G (Graves et al., 1995; Von Manteuel et al., 1996; Brunn et al., 1997) , thus potentially altering the conformation of the latter (Ohlmann et al., 1997) . However, to date, there is no evidence that the other inducers of apoptosis used in our studies impinge upon the mTOR signalling pathway and no reason to believe that the activation of this pathway would be aected by caspase inhibitors. Moreover, as indicated earlier, although rapamycin blocks the activation of the mTOR/p70 S6 kinase signalling pathway it is unable to prevent the cleavage of eIF4G that occurs after cycloheximide treatment.
The physiological consequences of eIF4G loss in apoptosing cells remain to be investigated. Depending on the site(s) of cleavage and the stabilities of the products, fragments may be generated that in¯uence the spectrum of proteins synthesized by the cell (JoshiBarve et al., 1992) . This phenomenon is well established in the case of cleavage by picornaviral proteases, where the C-terminal cleavage product can still interact with eIF3 and eIF4A and can promote the translation of internally initiated and uncapped mRNAs at the expense of capped mRNAs (Lloyd et al., 1987; Ohlmann et al., 1995 Ohlmann et al., , 1996 Borman et al., 1997; Novoa et al., 1997) . However, cleavage at other sites and/or further degradation of eIF4G to smaller fragments may result in the factor rapidly becoming rate-limiting for overall protein synthesis. Thus it is possible that the loss of eIF4G contributes to the marked shut-o of translation that occurs as apoptosis proceeds (Deckwerth and Johnson, 1993; Zakeri et al., 1996; S. Morley, unpublished data) .
Finally, it is not known whether high level expression of eIF4G might protect cells against apoptosis, as has been shown in the case of eIF4E (Polunovsky et al., 1996) . Over-expression of the factor has been reported to cause malignant transformation (Fukuchi-Shimogori et al., 1997) . Intriguingly, a fragment of a gene that encodes a mammalian homologue of the C-terminal part of eIF4G, variously called p97, DAP-5 or NAT1 Levy-Strumpf et al., 1997; Yamanaka et al., 1997) , has been reported to protect HeLa cells against interferong-induced apoptosis. The functional relationship, if any, of p97/DAP-5/NAT1 to the ca. 76 kDa eIF4G cleavage fragment observed in apoptotic cells remains to be established, but preliminary data suggest that the properties of the two proteins are distinct. The 76 kDa fragment does not appear to protect cells against apoptosis since it is observed only under conditions in which this process is taking place. If intact eIF4G (or a related protein) can indeed inhibit apoptosis (perhaps by promoting the synthesis of crucial anti-apoptotic proteins), but is also itself a target for apoptotic cleavage, giving rise to the ca. 76 kDa form, the progressive loss of the full-length factor might be expected to lead to irreversible cellular catastrophe and the acceleration of cell death.
Materials and methods
Reagents
Tissue culture materials were purchased from Life Technologies. [
35 S]methionine was purchased from ICN. Cycloheximide and etoposide were obtained from SigmaAldrich. Anti-Fas antibody (clone CH-11) was provided by Upstate Biotechnology. The caspase inhibitors Z-VAD.FMK and Z-DEVD.FMK were purchased from Alexis Biochemicals or Calbiochem. Rapamycin was a gift from Dr J Kay (University of Sussex, UK). Antibodies to the 4E-BPs and poly(A)-binding protein were kind gifts from Dr AA Thomas (University of Utrecht) and Dr D Schoenberg (Ohio State University, USA), respectively. Antibody to poly(ADP-ribose) polymerase (PARP) was obtained from Boehringer. A rabbit antiserum was raised against the C-terminal portion of eIF4G (amino acids 920 ± 1396; Pestova et al., 1996) . The antibodies against eIF4E, eIF4A and eIF2a were as described previously (Scorsone et al., 1987; Ohlmann et al., 1997) .
Cell culture
BJAB cells are an EBV-negative cell line derived from a human Burkitt's lymphoma. Jurkat J6 cells are a T-cell line derived from a human lymphoblastic leukaemia. Both cell lines were grown in stationary suspension culture in RPMI 1640 medium supplemented with glutamine (300 mg/l) or GlutaMAX TM (446 mg/l) (Life Technologies), 10% (v/v) foetal calf serum, penicillin (100 units/ml) and streptomycin (100 mg/ml), in a 5% CO 2 atmosphere at 378C. Cells were maintained at densities between 2.5 and 8610 5 cells per ml.
Induction and assay of apoptosis
Cell growth arrest and apoptosis were induced in BJAB cells by replacing the growth medium with an otherwise identical medium containing only 0.1% (v/v) foetal calf serum for up to 2 days, or by adding anti-Fas antibody (150 ng/ml), etoposide (100 mg/ml) or cycloheximide (100 mg/ml), as described in the ®gure legends. Apoptosis in Jurkat cells was induced by similar treatment with cycloheximide or anti-Fas antibody. Where indicated cells were preincubated with agents previously shown to inhibit caspase activity, viz. Z-VAD.FMK, Z-DEVD.FMK or ZnCl 2 , before exposure to the apoptosis-inducing conditions. The progress of apoptosis was monitored in intact cells by the cleavage of the caspase substrate PARP (Kaufmann et al., 1993) and/or by the appearance of cells with less than the G1 content of DNA (analysed bȳ uorescence-activated cell sorting; Milner et al., 1995) .
Measurement of protein synthesis
The overall rate of protein synthesis in intact cells was measured by the incorporation of [ 35 S]methionine into trichloroacetic acid-insoluble material. After pulse-labelling for 1 h with up to 15 mCi/ml of the radioactive amino acid (in the presence of the normal level of methionine in the cell culture medium), cells were brie¯y centrifuged, washed once in cold phosphate-buered saline containing 100 mM unlabelled methionine, dissolved in 0.3 M NaOH and precipitated with 10% trichloroacetic acid in the presence of 0.5 mg bovine serum albumin carrier protein. Precipitates were washed with 5% trichloroacetic acid and industrial methylated spirit and the radioactivity determined by scintillation counting.
Preparation of cell extracts
Cytoplasmic extracts of cells were prepared for immunoblotting by lysing the cells in a buer containing a cocktail of protease and protein phosphatase inhibitors. The composition of the lysis buer was: 50 mM MOPS (3-[NMorpholino]propanesulphonic acid), pH 7.4, 50 mM NaCl, 2 mM EDTA, 2 mM EGTA, 50 mM b-glycerophosphate, 1 mM microcystin, 2 mM benzamidine, 2 mM Na vanadate, 5 mM p-nitrophenylphosphate, 1 mM PMSF, 0.1 mM GTP and 7 mM 2-mercaptoethanol. The cells were washed by centrifugation and resuspension twice in phosphatebuered saline containing 50 mM b-glycerophosphate, and once in lysis buer without detergent. After a ®nal centrifugation for 1 min in a refrigerated microfuge the cells were drained and resuspended in lysis buer (5 ml per 10 6 cells) and Nonidet P-40 or Igepal CA-630 (Sigma) added to a ®nal concentration of 0.2% (v/v). The suspensions were vortexed vigorously and centrifuged for 5 min in a microfuge at 48C to remove nuclei. The supernatants were rapidly frozen in small aliquots at 7808C.
Isolation of eIF4E and associated proteins by m 7 GTP-Sepharose chromatography
Initiation factor eIF4E and proteins bound to it were isolated from cell extracts by anity chromatography on m 7 GTP-Sepharose as previously described (Morley and Pain, 1995a,b) . Brie¯y, cytoplasmic extracts were diluted with lysis buer and mixed with m 7 GTP-Sepharose at 48C for 10 min. After washing twice with 250 ml of lysis buer the proteins were eluted from the resin with SDS sample buer.
Immunoblotting and densitometry
Cell extracts and m 7 GTP-Sepharose-puri®ed fractions were subjected to electrophoresis on 7.5%, 10% or 15% polyacrylamide SDS gels (according to the size of the proteins to be analysed) and transferred to PVDF membranes (Millipore) using a semi-dry blotting apparatus (Hoefer). In each experiment equal amounts of protein were loaded in each lane of the gel (within the range 3 ± 10 mg protein per sample in the case of total cytoplasmic extracts, depending on the sensitivity of the antibody to be used). Fractions puri®ed from equal amounts of cell extract (ca. 40 mg protein) by anity chromatography on m 7 GTPSepharose were analysed similarly. Blots were blocked, incubated with the appropriate primary antibodies (see Figure legends) and developed using alkaline phosphataselinked secondary antibodies with NBT as the substrate, under standard conditions (Morley and Pain, 1995a) . The blots were analysed by densitometry using a scanning laser Personal Densitometer SI (Molecular Dynamics) employing ImageQuant software or a Sharp JX-325 scanner with Image Master software (Pharmacia Biotech). In all cases, detection was in the linear range of the antiserum employed for decoration of resolved proteins. 
